Momenta Pharma (MNTA) Stock Price, Forecast & Analysis
USA - NASDAQ:MNTA -
MNTA Key Statistics, Chart & Performance
The current stock price of MNTA is 52.48 null. In the past month the price increased by 0.63%. In the past year, price increased by 300.15%.
MNTA Latest News, Press Relases and Analysis
About MNTA
Company Profile
Momenta Pharmaceuticals is a leader in the analysis, characterization and design of complex pharmaceutical products. Their scientific foundation is a set of tools and methods that allow them to develop a deep understanding of the links between a compound's chemical structure, biological function and its manufacturing process. They are applying their innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
Company Info
Momenta Pharma
301 BINNEY STREET
CAMBRIDGE MA 02142
CEO: Craig A. Wheeler
Phone: 617-491-9700
Momenta Pharma / MNTA FAQ
What does MNTA do?
Momenta Pharmaceuticals is a leader in the analysis, characterization and design of complex pharmaceutical products. Their scientific foundation is a set of tools and methods that allow them to develop a deep understanding of the links between a compound's chemical structure, biological function and its manufacturing process. They are applying their innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
What is the current price of MNTA stock?
The current stock price of MNTA is 52.48 null. The price decreased by -0.02% in the last trading session.
What is the dividend status of Momenta Pharma?
MNTA does not pay a dividend.
How is the ChartMill rating for Momenta Pharma?
MNTA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of Momenta Pharma (MNTA) based on its PE ratio?
Momenta Pharma (MNTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.23).
MNTA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MNTA. When comparing the yearly performance of all stocks, MNTA is one of the better performing stocks in the market, outperforming 98.46% of all stocks.
MNTA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNTA. While MNTA has a great health rating, there are worries on its profitability.
MNTA Financial Highlights
Over the last trailing twelve months MNTA reported a non-GAAP Earnings per Share(EPS) of -2.23. The EPS decreased by -4.21% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -757.62% | ||
| ROA | -43.54% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |